Bioblast Pharma Ltd (NASDAQ:ORPN)’s share price fell 14% during mid-day trading on Wednesday . The company traded as low as $1.32 and last traded at $1.35. 1,342,348 shares were traded during trading, an increase of 806% from the average session volume of 148,131 shares. The stock had previously closed at $1.57.
Separately, ValuEngine upgraded Bioblast Pharma from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.
TRADEMARK VIOLATION NOTICE: This news story was published by WKRB News and is the property of of WKRB News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.wkrb13.com/2018/11/08/bioblast-pharma-orpn-trading-down-14.html.
Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3.
Read More: How analysts view the yield curve
Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.